From: A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer
ICGC-PACA-CA cohort (Training) | TCGA-PAAD cohort (Testing) | ||||||
---|---|---|---|---|---|---|---|
Characteristics | Number of cases | % (percentage) | Characteristics | Number of cases | % (percentage) | ||
Age | Â | Â | Â | Age | Â | Â | Â |
 | <=65 | 78 | 42.86 |  | <=65 | 93 | 52.54 |
 | > 65 | 86 | 47.25 |  | > 65 | 84 | 47.46 |
 | Unknown | 18 | 9.89 |  | Unknown | 0 | 0 |
Gender | Â | Â | Â | Gender | Â | Â | Â |
 | Male | 99 | 54.40 |  | Male | 97 | 54.80 |
 | Female | 82 | 45.05 |  | Female | 80 | 45.20 |
 | Unknown | 1 | 0.55 |  | Unknown | 0 | 0 |
Stage | Â | Â | Â | Stage | Â | Â | Â |
 | Stage I | 51 | 28.02 |  | Stage I | 22 | 12.43 |
 | Stage II | 85 | 46.70 |  | Stage II | 148 | 83.62 |
 | Stage III-IV | 8 | 4.40 |  | Stage III-IV | 7 | 3.95 |
 | Unknown | 38 | 20.88 |  | Unknown | 0 | 0 |
Grade | Â | Â | Â | Grade | Â | Â | Â |
 | G1 | NA | NA |  | G1 | 31 | 17.51 |
 | G2 | NA | NA |  | G2 | 94 | 53.11 |
 | G3–4 | NA | NA |  | G3–4 | 50 | 28.25 |
 | Unknown | NA | NA |  | Unknown | 2 | 1.13 |